T cells exist in many functional states, and dynamic transitions from one state to another affect the outcome of adoptive T cell therapy. FOXP1 and KLF2 are now identified as transcriptional regulators of the stemness of CD8+ CAR-T cells and the bifurcation of stem-like CD8+ CAR-T cells into effector and exhausted subsets, respectively.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Jiang, P. et al. Leukemia 36, 2656–2668 (2022).
Riegel, D. et al. Mol. Cell 83, 622–636.e10 (2023).
Zhu, Z. et al. Nat. Immunol. https://doi.org/10.1038/s41590-023-01685-w (2023).
Tsui, C. et al. Nature 609, 354–360 (2022).
Locke, F. L. et al. Lancet Oncol. 20, 31–42 (2019).
Qi, C. et al. Nat. Med. 28, 1189–1198 (2022).
Chen, G. M. et al. Cancer Discov. 11, 2186–2199 (2021).
Gueguen, P. et al. Sci Immunol. 6, eabd5778 (2021).
Arcangeli, S. et al. J. Clin. Invest. 132, e150807 (2022).
Melenhorst, J. J. et al. Nature 602, 503–509 (2022).
You, L. et al. Front. Immunol. 11, 1787 (2020).
Gambacorta, V. et al. Cancer Discov. 12, 1449–1461 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
M.C., C.B. and E.R. are inventors on different patents on cancer immunotherapy and genome editing (E.R.: PCT/EP2018/060477, PCT/EP2019/079916 and PCT/EP2022/053040; C.B.: PCT/IT2006/000600, 12/927,292, PCT/US2014/031360, PCT/IB2015/057049, PCT/EP2018/060477, PCT/EP2019/079916, PCT/EP2021/061198 and PCT/EP2022/053040; M.C.: PCT/IB2015/057049, PCT/EP2021/061198 and PCT/EP2019/069712). M.C. has received research support from Kite/Gilead. C.B. has been a member of advisory boards and a consultant for Intellia Therapeutics, TxCell, Novartis, GSK, Allogene, Kite/Gilead, Miltenyi, Kiadis and Janssen, and received research support from Intellia Therapeutics.
Rights and permissions
About this article
Cite this article
Casucci, M., Bonini, C. & Ruggiero, E. Epigenetic checkpoints regulate the fate and function of CAR-T cells. Nat Immunol 25, 4–6 (2024). https://doi.org/10.1038/s41590-023-01708-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41590-023-01708-6